[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transitional-cell-carcinoma-of-renal-pelvis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transitional-cell-carcinoma-of-renal-pelvis":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":34,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100506479","utract-jelmyto-registry-a-registry-of-patients-with-upper-tract-urothelial-cancer-utuc-treated-with-jelmyto-100506479",false,"NCT05874921","uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto","uTRACT Jelmyto Registry: A Multicenter, Prospective and Retrospective Registry to Evaluate Real World Experience and Outcomes of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto","uTRACT","Inclusion Criteria:\n\n* Adults \\>18 years old and capable of giving informed consent.\n* Diagnosis of UTUC.\n* Receipt of at least 1 dose of JELMYTO after FDA approval (15 Apr 2020).\n\nExclusion Criteria:\n\n* Incapable of giving informed consent (e.g., incarcerated individuals, individuals with dementia).\n* Receipt of 1 or more doses of JELMYTO (also referred to as UGN-101 or Mitogel in clinical development) before FDA approval (on or before 15 Apr 2020).\n* Pregnancy or lactation.\n* Unable to comply with protocol requirements (for prospective data capture).\n* Any medical or mental condition(s) that makes participation in the Registry inadvisable in the opinion of the Investigator (for prospective data capture).","ALL","18 Years",{"count":20,"type":21},400,"ESTIMATED","3 Years","OBSERVATIONAL","The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.",[26,27,28,29,30,31,32,33],"Urothelial Carcinoma","Urothelial Carcinoma Recurrent","Urothelial Carcinoma Ureter","Urothelial Carcinoma Ureter Recurrent","Urothelial Cancer of Renal Pelvis","Urothelial Carcinoma of the Renal Pelvis and Ureter","Carcinoma, Transitional Cell","Transitional Cell Carcinoma of Renal Pelvis",[35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60],"Upper Tract Urothelial Cancer","UTUC","UGN-101","Mitomycin C","TCC","Ureteral","Upper Tract","Carcinoma","Kidney","Renal","Gel","Local","Prolonged Release","Slow Release","Kidney Sparing","Recurrence","Neoplasms by Histologic Type","Neoplasms","Urologic Neoplasms","Urogenital Neoplasms","Neoplasms by Site","Antibiotics, Antineoplastic","Antineoplastic Agents","Alkylating Agents","Nucleic Acid Synthesis Inhibitors","Enzyme Inhibitors","RECRUITING","2025-02-25",{"date":64,"type":65},"2025-02-28","ACTUAL",{"date":67,"type":65},"2023-11-17",{"date":69,"type":21},"2028-01",{"name":71,"class":72},"UroGen Pharma Ltd.","INDUSTRY",22]